2024 Q2 Form 10-Q Financial Statement
#000121723424000064 Filed on May 09, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| Revenue | $92.27M | $72.05M |
| YoY Change | 31.26% | -6.75% |
| Cost Of Revenue | $27.95M | $25.93M |
| YoY Change | 7.95% | -0.12% |
| Gross Profit | $64.33M | $46.12M |
| YoY Change | 44.84% | -10.1% |
| Gross Profit Margin | 69.71% | 64.01% |
| Selling, General & Admin | $48.68M | $46.74M |
| YoY Change | -4.47% | -8.82% |
| % of Gross Profit | 75.67% | 101.36% |
| Research & Development | $19.68M | $18.71M |
| YoY Change | -2.74% | -23.18% |
| % of Gross Profit | 30.59% | 40.57% |
| Depreciation & Amortization | $3.543M | $3.821M |
| YoY Change | -3.36% | 11.5% |
| % of Gross Profit | 5.51% | 8.29% |
| Operating Expenses | $96.37M | $91.39M |
| YoY Change | -1.59% | -10.04% |
| Operating Profit | -$4.098M | -$19.34M |
| YoY Change | -85.17% | -20.5% |
| Interest Expense | $2.826M | $2.885M |
| YoY Change | -1.57% | 8.21% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $2.726M | $2.595M |
| YoY Change | 4.73% | 271.24% |
| Pretax Income | -$1.372M | -$16.74M |
| YoY Change | -94.52% | -29.13% |
| Income Tax | $22.00K | -$83.00K |
| % Of Pretax Income | ||
| Net Earnings | -$1.394M | -$16.66M |
| YoY Change | -94.41% | -29.85% |
| Net Earnings / Revenue | -1.51% | -23.12% |
| Basic Earnings Per Share | -$0.03 | -$0.32 |
| Diluted Earnings Per Share | -$0.03 | -$0.32 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 52.08M shares | 51.78M shares |
| Diluted Shares Outstanding | 52.20M shares | 51.69M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $228.9M | $215.9M |
| YoY Change | -19.98% | -25.17% |
| Cash & Equivalents | $95.78M | $93.30M |
| Short-Term Investments | $133.1M | $122.6M |
| Other Short-Term Assets | $6.343M | $6.895M |
| YoY Change | -17.37% | -15.51% |
| Inventory | $19.23M | $20.13M |
| Prepaid Expenses | ||
| Receivables | $66.16M | $60.15M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $320.6M | $303.1M |
| YoY Change | -11.14% | -18.4% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $34.20M | $34.41M |
| YoY Change | -5.22% | -3.08% |
| Goodwill | $40.30M | $40.30M |
| YoY Change | 1.51% | 1.77% |
| Intangibles | $41.90M | $43.33M |
| YoY Change | -3.75% | -5.06% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $1.958M | $2.060M |
| YoY Change | -3.83% | -0.96% |
| Total Long-Term Assets | $146.2M | $149.3M |
| YoY Change | -5.09% | -4.77% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $320.6M | $303.1M |
| Total Long-Term Assets | $146.2M | $149.3M |
| Total Assets | $466.8M | $452.4M |
| YoY Change | -9.33% | -14.35% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $5.874M | $9.976M |
| YoY Change | -40.55% | -22.43% |
| Accrued Expenses | $40.85M | $30.84M |
| YoY Change | 4.47% | -9.33% |
| Deferred Revenue | $5.852M | $4.356M |
| YoY Change | -3.4% | -25.42% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $78.33M | $70.21M |
| YoY Change | 5.15% | -2.25% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $96.72M | $97.69M |
| YoY Change | 39058.3% | 39289.52% |
| Total Long-Term Liabilities | $96.72M | $97.69M |
| YoY Change | 39058.3% | 39289.52% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $78.33M | $70.21M |
| Total Long-Term Liabilities | $96.72M | $97.69M |
| Total Liabilities | $202.1M | $196.2M |
| YoY Change | 84.39% | 81.32% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$696.8M | -$695.5M |
| YoY Change | 36.65% | 43.43% |
| Common Stock | $969.5M | $959.8M |
| YoY Change | 4.97% | 5.2% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $264.7M | $256.2M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $466.8M | $452.4M |
| YoY Change | -9.33% | -14.35% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$1.394M | -$16.66M |
| YoY Change | -94.41% | -29.85% |
| Depreciation, Depletion And Amortization | $3.543M | $3.821M |
| YoY Change | -3.36% | 11.5% |
| Cash From Operating Activities | $18.95M | -$15.31M |
| YoY Change | -3897.39% | -2381.97% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $1.790M | $1.487M |
| YoY Change | -24.22% | -46.34% |
| Acquisitions | $0.00 | |
| YoY Change | -100.0% | |
| Other Investing Activities | -$9.836M | $29.15M |
| YoY Change | -155.54% | -342.89% |
| Cash From Investing Activities | -$11.63M | $27.66M |
| YoY Change | -175.75% | -287.26% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -4.850M | -$1.275M |
| YoY Change | 209.71% | 12.04% |
| NET CHANGE | ||
| Cash From Operating Activities | 18.95M | -$15.31M |
| Cash From Investing Activities | -11.63M | $27.66M |
| Cash From Financing Activities | -4.850M | -$1.275M |
| Net Change In Cash | 2.473M | $11.10M |
| YoY Change | -81.38% | -172.72% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $18.95M | -$15.31M |
| Capital Expenditures | $1.790M | $1.487M |
| Free Cash Flow | $17.16M | -$16.80M |
| YoY Change | -699.76% | 699.95% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities | |
| CY2024Q1 | us-gaap |
Defined Benefit Plan Type Extensible List
DefinedBenefitPlanTypeExtensibleList
|
http://fasb.org/us-gaap/2023#PostemploymentRetirementBenefitsMember | |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
51782612 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
51782612 | shares |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
72049000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
77262000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
18711000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24357000 | usd |
| CY2024Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
19830000 | usd |
| CY2023Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
23231000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
26911000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
28032000 | usd |
| CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
91386000 | usd |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
101586000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19337000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-24324000 | usd |
| CY2024Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
2885000 | usd |
| CY2023Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
2666000 | usd |
| CY2024Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
0 | usd |
| CY2023Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
7000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-290000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1974000 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2595000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
699000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-16742000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-23625000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-83000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
124000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16659000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23749000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.32 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.44 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.32 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.44 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
51692358 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53643216 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
51692358 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53643216 | shares |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-16659000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-23749000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1145000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
64000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-17804000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-23685000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
261328000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
532000 | usd |
| CY2024Q1 | us-gaap |
Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
|
522000 | usd |
| CY2024Q1 | us-gaap |
Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
|
-668000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
56000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
8000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
13295000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1145000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
256225000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
430911000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
456000 | usd |
| CY2023Q1 | us-gaap |
Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
|
690000 | usd |
| CY2023Q1 | us-gaap |
Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
|
-785000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
93000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
13719000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
64000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23749000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
420021000 | usd |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-16659000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-23749000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13344000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13754000 | usd |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-7000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3821000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3427000 | usd |
| CY2024Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | usd |
| CY2023Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
1000000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
1402000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
1337000 | usd |
| CY2024Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
0 | usd |
| CY2023Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-905000 | usd |
| CY2024Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
319000 | usd |
| CY2023Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
364000 | usd |
| CY2024Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-1451000 | usd |
| CY2023Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
773000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
9199000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-7664000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1274000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-1217000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-108000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-1515000 | usd |
| CY2024Q1 | cdna |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-1372000 | usd |
| CY2023Q1 | cdna |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-1333000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2897000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
2590000 | usd |
| CY2022Q4 | us-gaap |
Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
|
P2Y | |
| CY2024Q1 | us-gaap |
Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
|
55500 | shares |
| CY2024Q1 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
500000 | usd |
| CY2024Q1 | us-gaap |
Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
|
21400000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
-4820000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
-4888000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
557000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-2352000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
93000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
0 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-15312000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
671000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
4562000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
57746000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
86310000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
86893000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
78972000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
|
100000 | usd |
| CY2024Q1 | cdna |
Payments To Acquire Capital Expenditures Net
PaymentsToAcquireCapitalExpendituresNet
|
1487000 | usd |
| CY2023Q1 | cdna |
Payments To Acquire Capital Expenditures Net
PaymentsToAcquireCapitalExpendituresNet
|
2771000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
27660000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-14771000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
532000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
456000 | usd |
| CY2024Q1 | cdna |
Taxes Paid Related To Net Share Settlement Of Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
|
668000 | usd |
| CY2023Q1 | cdna |
Taxes Paid Related To Net Share Settlement Of Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
|
656000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
8000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2000 | usd |
| CY2024Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
625000 | usd |
| CY2023Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
250000 | usd |
| CY2024Q1 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
522000 | usd |
| CY2023Q1 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
690000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1275000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1138000 | usd |
| CY2024Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
26000 | usd |
| CY2023Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-25000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
11099000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-15263000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82783000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
90443000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93882000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
75180000 | usd |
| CY2018Q1 | cdna |
Number Of Renal Transplant Patients
NumberOfRenalTransplantPatients
|
1900 | patient |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-695500000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
215900000 | usd |
| CY2023Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
250000000 | shares |
| CY2022Q4 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
50000000 | usd |
| CY2024Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
7398000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies; inventory valuation; the fair value of assets and liabilities acquired in a business combination or an asset acquisition (including identifiable intangible assets acquired); the fair value of contingent </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div> | |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, approximately 33% and 42%, respectively, of total revenue was derived from Medicare.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, approximately 37% and 36%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either March 31, 2024 or December 31, 2023.</span></div> | |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-16659000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-16659000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-23749000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-23749000 | usd |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
51692358 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
51692358 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53643216 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53643216 | shares |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.32 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.32 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.44 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.44 | |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10218943 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7347842 | shares |
| CY2023Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
7930000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
|
-1000000 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
93299000 | usd |
| CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
74660000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
583000 | usd |
| CY2023Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
520000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93882000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
75180000 | usd |
| CY2024Q1 | us-gaap |
Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
|
0 | usd |
| CY2024Q1 | cdna |
Marketable Securities Amortized Cost Short Term
MarketableSecuritiesAmortizedCostShortTerm
|
122622000 | usd |
| CY2024Q1 | cdna |
Marketable Securities Accumulated Unrecognized Holding Gain Loss Short Term
MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm
|
1227000 | usd |
| CY2024Q1 | cdna |
Marketable Securities Fair Value Short Term
MarketableSecuritiesFairValueShortTerm
|
123849000 | usd |
| CY2023Q4 | cdna |
Marketable Securities Amortized Cost Short Term
MarketableSecuritiesAmortizedCostShortTerm
|
153221000 | usd |
| CY2023Q4 | cdna |
Marketable Securities Accumulated Unrecognized Holding Gain Loss Short Term
MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm
|
2749000 | usd |
| CY2023Q4 | cdna |
Marketable Securities Fair Value Short Term
MarketableSecuritiesFairValueShortTerm
|
155970000 | usd |
| CY2023Q3 | us-gaap |
Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
|
2600000 | usd |
| CY2023Q3 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
1800000 | usd |
| CY2023Q3 | us-gaap |
Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
|
500000 | usd |
| CY2023Q3 | us-gaap |
Asset Acquisition Consideration Transferred Transaction Cost
AssetAcquisitionConsiderationTransferredTransactionCost
|
300000 | usd |
| CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
40300000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
79884000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
35297000 | usd |
| CY2024Q1 | cdna |
Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
|
5007000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
39580000 | usd |
| CY2024Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
3750000 | usd |
| CY2024Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
3750000 | usd |
| CY2024Q1 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
83634000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
35297000 | usd |
| CY2024Q1 | cdna |
Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
|
5007000 | usd |
| CY2024Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
43330000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
79884000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
33643000 | usd |
| CY2023Q4 | cdna |
Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
|
4516000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
41725000 | usd |
| CY2023Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
3976000 | usd |
| CY2023Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
3976000 | usd |
| CY2023Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
83860000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
33643000 | usd |
| CY2023Q4 | cdna |
Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
|
4516000 | usd |
| CY2023Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
45701000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1653000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1590000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
4687000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
6159000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
5245000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
5231000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
5231000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
13027000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
39580000 | usd |
| CY2024Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
4376000 | usd |
| CY2023Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
3658000 | usd |
| CY2024Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
5282000 | usd |
| CY2023Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
5191000 | usd |
| CY2024Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
10472000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
10622000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
20130000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
19471000 | usd |
| CY2024Q1 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
15133000 | usd |
| CY2023Q4 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
15744000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6054000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
5943000 | usd |
| CY2024Q1 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
6050000 | usd |
| CY2023Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
5469000 | usd |
| CY2024Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
4390000 | usd |
| CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
5911000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
4356000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
4748000 | usd |
| CY2024Q1 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
2933000 | usd |
| CY2023Q4 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
2890000 | usd |
| CY2024Q1 | cdna |
Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
|
920000 | usd |
| CY2023Q4 | cdna |
Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
|
920000 | usd |
| CY2024Q1 | cdna |
Accrued Travel And Expenses
AccruedTravelAndExpenses
|
891000 | usd |
| CY2023Q4 | cdna |
Accrued Travel And Expenses
AccruedTravelAndExpenses
|
0 | usd |
| CY2024Q1 | cdna |
Accrued Shipping Expenses
AccruedShippingExpenses
|
510000 | usd |
| CY2023Q4 | cdna |
Accrued Shipping Expenses
AccruedShippingExpenses
|
335000 | usd |
| CY2024Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
197000 | usd |
| CY2023Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
348000 | usd |
| CY2024Q1 | cdna |
Accrued License And Other Collaboration Fees
AccruedLicenseAndOtherCollaborationFees
|
88000 | usd |
| CY2023Q4 | cdna |
Accrued License And Other Collaboration Fees
AccruedLicenseAndOtherCollaborationFees
|
250000 | usd |
| CY2024Q1 | cdna |
Accrued Capital Expenditures
AccruedCapitalExpenditures
|
0 | usd |
| CY2023Q4 | cdna |
Accrued Capital Expenditures
AccruedCapitalExpenditures
|
151000 | usd |
| CY2024Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4148000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2788000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
45670000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
45497000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
28600000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6100000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
26900000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1971000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1983000 | usd |
| CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
1971000 | usd |
| CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
1983000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y2M15D | |
| CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y5M4D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.071 | |
| CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.071 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
6065000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
7922000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
7163000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
7274000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
6599000 | usd |
| CY2024Q1 | cdna |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
4116000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
39139000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
6192000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
32947000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6054000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
26893000 | usd |
| CY2024Q1 | cdna |
Lessee Operating Lease Sublease Term Arrangement
LesseeOperatingLeaseSubleaseTermArrangement
|
P6Y | |
| CY2024Q1 | cdna |
Lessee Operating Lease Sublease Base Rent
LesseeOperatingLeaseSubleaseBaseRent
|
2600000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1361000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1333000 | usd |
| CY2022Q4 | us-gaap |
Malpractice Insurance Maximum Coverage Per Incident
MalpracticeInsuranceMaximumCoveragePerIncident
|
15000000 | usd |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
|
172000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
2903 | shares |
| CY2024Q1 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
1600000 | usd |
| CY2023Q1 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
700000 | usd |
| CY2023Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
0 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
869111 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3055208 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
25.21 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
2060135 | shares |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services
ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices
|
6813 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
2716211 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
1501 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
5.63 | |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans
|
65601 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
158348 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
13190 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
13190 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
28.32 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
66475 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
66475 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
30.46 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
509836 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2974042 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
25.08 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | usd |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
|
1982 | shares |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
|
25.24 | |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
|
P6Y6M10D | |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
|
1483000 | usd |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
|
921 | shares |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
|
24.58 | |
| CY2024Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
|
P8Y4M17D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
1655000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13344000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13754000 | usd |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | usd |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
0 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-100000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
100000 | usd |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
72049000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
77262000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
34411000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
35246000 | usd |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
